Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure

European Journal of Heart Failure

Volumn 17, Issue 8, 2015, Pages 772-781

  Kadota, Shin ^a   Carey, John ^c   Reinecke, Hans ^a   Leggett, James ^d   Teichman, Sam ^d   Laflamme, Michael A ^a   Murry, Charles E ^a,b   Regnier, Michael ^a,b   Mahairas, Gregory G ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b University of Washington   (United States)

^c North American Science Asocites Inc   (United States)

^d BEAT Biotherapeutics Corp   (United States)

Author keywords

2 deoxy ATP; Gene therapy; Heart failure; Ribonucleotide reductase

Indexed keywords

CARDIAC MYOSIN; DEOXYADENOSINE TRIPHOSPHATE; PARVOVIRUS VECTOR; PLACEBO; RIBONUCLEOTIDE REDUCTASE; 2'-DEOXYADENOSINE TRIPHOSPHATE; DEOXYADENOSINE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR GENE THERAPY; CARDIOVASCULAR PARAMETERS; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE SIZE; HEART PERFORMANCE; HISTOPATHOLOGY; HUMORAL IMMUNITY; INOTROPISM; INTRACORONARY DRUG ADMINISTRATION; LEFT VENTRICULAR FRACTIONAL SHORTENING; LOW DRUG DOSE; MINIPIG; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BLOOD PRESSURE; CHRONIC DISEASE; COMPLICATION; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; HEART INFARCTION; HEART VENTRICLE; HEMODYNAMICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PIG; PROCEDURES; SYSTOLE;

ANIMALS; BLOOD PRESSURE; CHRONIC DISEASE; DEOXYADENINE NUCLEOTIDES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GENETIC THERAPY; GENETIC VECTORS; HEART FAILURE; HEART VENTRICLES; HEMODYNAMICS; HUMANS; MYOCARDIAL INFARCTION; PILOT PROJECTS; RIBONUCLEOTIDE REDUCTASES; SWINE; SWINE, MINIATURE; SYSTOLE;

EID: 84938553472     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.270     Document Type: Article

References (25)

1. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ,. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 2008; 51: 1112-1119.
2. Beeri R, Chaput M, Guerrero JL, Kawase Y, Yosefy C, Abedat S, Karakikes I, Morel C, Tisosky A, Sullivan S, Handschumacher MD, Gilon D, Vlahakes GJ, Hajjar RJ, Levine RA,. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail 2010; 3: 627-634.
3. Katz MG, Fargnoli AS, Williams RD, Steuerwald NM, Isidro A, Ivanina AV, Sokolova IM, Bridges CR,. Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy. J Thorac Cardiovasc Surg 2014; 148: 1065-1073.e2.
4. Pleger ST, Shan C, Ksienzyk J, Bekeredjian R, Boekstegers P, Hinkel R, Schinkel S, Leuchs B, Ludwig J, Qiu G, Weber C, Raake P, Koch WJ, Katus HA, Muller OJ, Most P,. Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med 2011; 3:92ra64.
5. Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, Ritterhoff J, Jungmann A, Remppis AB, Stangassinger M, Koch WJ, Katus HA, Muller OJ, Most P, Pleger ST,. Therapeutic safety of high myocardial expression levels of the molecular inotrope S100A1 in a preclinical heart failure model. Gene Ther 2014; 21: 131-138.
6. Katz MG, Fargnoli AS, Swain JD, Tomasulo CE, Ciccarelli M, Huang ZM, Rabinowitz JE, Bridges CR,. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg 2012; 143: 720-726.e3.
7. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S, Pleger S, Mier W, Haberkorn U, Koch WJ, Katus HA, Most P, Muller OJ,. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013; 34: 1437-1447.
8. Tilemann L, Lee A, Ishikawa K, Aguero J, Rapti K, Santos-Gallego C, Kohlbrenner E, Fish KM, Kho C, Hajjar RJ,. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med 2013; 5:211ra159.
9. Fish KM, Ladage D, Kawase Y, Karakikes I, Jeong D, Ly H, Ishikawa K, Hadri L, Tilemann L, Muller-Ehmsen J, Samulski RJ, Kranias EG, Hajjar RJ,. AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ Heart Fail 2013; 6: 310-317.
10. Ishikawa K, Fish KM, Tilemann L, Rapti K, Aguero J, Santos-Gallego CG, Lee A, Karakikes I, Xie C, Akar FG, Shimada YJ, Gwathmey JK, Asokan A, McPhee S, Samulski J, Samulski RJ, Sigg DC, Weber T, Kranias EG, Hajjar RJ,. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Mol Ther 2014; 22: 2038-2045.
11. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ,. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 + -ATPase in patients with advanced heart failure. Circulation 2011; 124: 304-313.
12. Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ,. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014; 114: 101-108.
13. Kashlan OB, Cooperman BS,. Comprehensive model for allosteric regulation of mammalian ribonucleotide reductase: refinements and consequences. Biochemistry 2003; 42: 1696-1706.
14. Regnier M, Rivera AJ, Chen Y, Chase PB,. 2-Deoxy-ATP enhances contractility of rat cardiac muscle. Circ Res 2000; 86: 1211-1217.
15. Regnier M, Martin H, Barsotti RJ, Rivera AJ, Martyn DA, Clemmens E,. Cross-bridge versus thin filament contributions to the level and rate of force development in cardiac muscle. Biophys J 2004; 87: 1815-1824.
16. Moussavi-Harami F, Razumova MV, Racca AW, Cheng Y, Stempien-Otero A, Regnier M,. 2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure. J Mol Cell Cardiol 2014; 79c: 256-263.
17. Korte FS, Dai J, Buckley K, Feest ER, Adamek N, Geeves MA, Murry CE, Regnier M,. Upregulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation. J Mol Cell Cardiol 2011; 51: 894-901.
18. Nowakowski SG, Kolwicz SC, Korte FS, Luo Z, Robinson-Hamm JN, Page JL, Brozovich F, Weiss RS, Tian R, Murry CE, Regnier M,. Transgenic overexpression of ribonucleotide reductase improves cardiac performance. Proc Natl Acad Sci USA 2013; 110: 6187-6192.
19. Lundy SD, Murphy SA, Dupras SK, Dai J, Murry CE, Laflamme MA, Regnier M,. Cell-based delivery of dATP via gap junctions enhances cardiac contractility. J Mol Cell Cardiol 2014; 72: 350-359.
20. Nowakowski SG, Adamek N, Geeves MA, Gay E, Kolwicz SC, Murry CE, Daggett V, Regnier M,. 2-Deoxy-ATP alters myosin structure to enhance cross-bridge cycling and improve cardiac function. Biophys J 2013; 104:17a.
21. Teerlink JR,. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2009; 14: 289-298.
22. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA,. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011; 378: 667-675.
23. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ Jr., Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett 2010; 1: 472-477.
24. Fairman JW, Wijerathna SR, Ahmad MF, Xu H, Nakano R, Jha S, Prendergast J, Welin RM, Flodin S, Roos A, Nordlund P, Li Z, Walz T, Dealwis CG,. Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization. Nat Struct Mol Biol 2011; 18: 316-322.
25. Schoffstall B, Clark A, Chase PB,. Positive inotropic effects of low dATP/ATP ratios on mechanics and kinetics of porcine cardiac muscle. Biophys J 2006; 91: 2216-2226.